JP2024506940A - Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 - Google Patents

Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 Download PDF

Info

Publication number
JP2024506940A
JP2024506940A JP2023549820A JP2023549820A JP2024506940A JP 2024506940 A JP2024506940 A JP 2024506940A JP 2023549820 A JP2023549820 A JP 2023549820A JP 2023549820 A JP2023549820 A JP 2023549820A JP 2024506940 A JP2024506940 A JP 2024506940A
Authority
JP
Japan
Prior art keywords
tl1a
dose
antibody
weeks
fcrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506940A5 (https=
JPWO2022178159A5 (https=
Inventor
ルオ，アリソン
オーツキ，ローレン
マニング，マーク
ペイン，ロバート
ローラン，オリヴィエ
ビルスボロー，ジャニーン
ヘンクル，ブラッドリー
アール． タルガン，ステファン
Original Assignee
プロメテウス バイオサイエンシーズ，インク．
シーダーズ―シナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロメテウス バイオサイエンシーズ，インク．, シーダーズ―シナイ メディカル センター filed Critical プロメテウス バイオサイエンシーズ，インク．
Publication of JP2024506940A publication Critical patent/JP2024506940A/ja
Publication of JP2024506940A5 publication Critical patent/JP2024506940A5/ja
Publication of JPWO2022178159A5 publication Critical patent/JPWO2022178159A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023549820A 2021-02-18 2022-02-17 Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 Pending JP2024506940A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163150825P 2021-02-18 2021-02-18
US63/150,825 2021-02-18
US202163180892P 2021-04-28 2021-04-28
US63/180,892 2021-04-28
US202163226037P 2021-07-27 2021-07-27
US63/226,037 2021-07-27
US202163285781P 2021-12-03 2021-12-03
US63/285,781 2021-12-03
PCT/US2022/016841 WO2022178159A1 (en) 2021-02-18 2022-02-17 Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Publications (3)

Publication Number Publication Date
JP2024506940A true JP2024506940A (ja) 2024-02-15
JP2024506940A5 JP2024506940A5 (https=) 2025-02-25
JPWO2022178159A5 JPWO2022178159A5 (https=) 2025-02-25

Family

ID=82931032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549820A Pending JP2024506940A (ja) 2021-02-18 2022-02-17 Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用

Country Status (19)

Country Link
US (1) US20240309104A1 (https=)
EP (1) EP4294444A4 (https=)
JP (1) JP2024506940A (https=)
KR (1) KR20230157973A (https=)
AU (1) AU2022223420A1 (https=)
BR (1) BR112023016672A2 (https=)
CA (1) CA3207817A1 (https=)
CL (1) CL2023002424A1 (https=)
CO (1) CO2023011969A2 (https=)
CR (1) CR20230436A (https=)
DO (1) DOP2023000162A (https=)
EC (1) ECSP23070237A (https=)
GE (2) GEAP202416596A (https=)
IL (1) IL305312A (https=)
JO (1) JOP20230185A1 (https=)
MX (1) MX2023009622A (https=)
PE (1) PE20231681A1 (https=)
TW (1) TW202246322A (https=)
WO (1) WO2022178159A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
EP4637819A1 (en) * 2022-12-22 2025-10-29 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
WO2024173838A2 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the bile duct
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
US12473370B2 (en) 2023-10-03 2025-11-18 Absci Corporation TL1A associated antibody compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539638A (ja) * 2013-11-13 2016-12-22 ファイザー・インコーポレイテッド 腫瘍壊死因子様リガンド１ａ特異的抗体ならびにその組成物および使用
JP2019522961A (ja) * 2016-05-09 2019-08-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｌ１ａ抗体およびその使用
WO2019209995A2 (en) * 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3375B1 (ar) * 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
WO2021081365A1 (en) * 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016539638A (ja) * 2013-11-13 2016-12-22 ファイザー・インコーポレイテッド 腫瘍壊死因子様リガンド１ａ特異的抗体ならびにその組成物および使用
JP2019522961A (ja) * 2016-05-09 2019-08-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｌ１ａ抗体およびその使用
WO2019209995A2 (en) * 2018-04-25 2019-10-31 Precision Ibd, Inc. Optimized anti-tl1a antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EUR. J. PHARM. BIOPHARM., vol. 78, JPN6024010936, 2011, pages 208 - 212, ISSN: 0005777480 *

Also Published As

Publication number Publication date
CA3207817A1 (en) 2022-08-25
BR112023016672A2 (pt) 2023-11-21
TW202246322A (zh) 2022-12-01
JOP20230185A1 (ar) 2023-08-09
DOP2023000162A (es) 2023-10-15
WO2022178159A1 (en) 2022-08-25
GEAP202316354A (en) 2023-12-25
MX2023009622A (es) 2023-08-28
IL305312A (en) 2023-10-01
CO2023011969A2 (es) 2023-09-29
AU2022223420A1 (en) 2023-09-21
EP4294444A1 (en) 2023-12-27
CR20230436A (es) 2023-11-01
KR20230157973A (ko) 2023-11-17
EP4294444A4 (en) 2025-04-16
GEAP202416596A (en) 2024-10-28
PE20231681A1 (es) 2023-10-19
US20240309104A1 (en) 2024-09-19
ECSP23070237A (es) 2023-10-31
CL2023002424A1 (es) 2024-01-05

Similar Documents

Publication Publication Date Title
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
US11999789B2 (en) Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
JP2024506940A (ja) Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用
TWI871367B (zh) 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
US20250243289A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
WO2023009545A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2024173877A1 (en) Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024173861A2 (en) Anti-tl1a antibody compositions and methods of treating skin
WO2024173838A2 (en) Anti-tl1a antibody compositions and methods of treatment in the bile duct
EP4637819A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
EP4676971A2 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
WO2024173865A2 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
EP4646443A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
EP4646434A2 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
CN118059231A (zh) 包括针对tnf样配体1a（tl1a）的人源化抗体的组合物以及其用途
CN117202932A (zh) 治疗肺部的抗tl1a抗体组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413